Oct4A is expressed by a subpopulation of prostate neuroendocrine cells

Sotomayor, Paula; Godoy, Alejandro; Smith, Gary J.; Huss, Wendy J.

doi:10.1002/pros.20895

Cited by 81 publications

(75 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A small minority of Oct-4 + cells (approximately 5%) were identified in perinecrotic areas ( Figure 1A, 2). All Oct-4 + cells displayed granular cytoplasmic (Golgi-like) and punctate nuclear staining patterns ( Figure 1A-1D), in accordance with other studies in bladder, prostate and lung cancers [37][38][39].…”

Section: Identification Of Oct-4 + Cells In Primary Nb Samples and Nbsupporting

confidence: 91%

Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells

Pezzolo¹,

Parodi²,

Marimpietri³

et al. 2011

Cell Res

View full text Add to dashboard Cite

show abstract

Section: Identification Of Oct-4 + Cells In Primary Nb Samples and Nbsupporting

confidence: 91%

Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells

Pezzolo¹,

Parodi²,

Marimpietri³

et al. 2011

Cell Res

View full text Add to dashboard Cite

show abstract

“…were identified in several somatic cancers [6]. Oct4A expressing cells are present in human benign and malignant prostate glands and the frequency of Oct4A expressing cells increases in prostate cancers [6].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Oct4A expressing cells are present in human benign and malignant prostate glands and the frequency of Oct4A expressing cells increases in prostate cancers [6]. A subpopulation of the Oct4A expressing cells coexpressed Sox2, an ES cell marker [6]. In the intestine, Oct4 expression causes dysplasia by inhibiting cellular differentiation in a manner similar to that in the ES cells [7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Embryonic stem cell markers expression in cancers

Schoenhals

Kassambara

Vos

et al. 2009

Biochemical and Biophysical Research Communications

221

202

View full text Add to dashboard Cite

Abstract:The transcription factors Oct4 and Sox2 are highly expressed in embryonic stem (ES) cells. In conjunction with Klf4 and c-Myc, their over-expression can induce pluripotency in both mouse and human somatic cells, indicating that these factors are key regulators of the signaling network necessary for ES cell pluripotency. Self-renewal is a hallmark of stem cells and cancer and stemness program could play an important role in cancer.Therefore we compared the expression of Oct4, Sox2, Klf4 and c-Myc in 40 human tumor types to that of their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray database.We found significant overexpression of at least 1/4 pluripotency factors Oct4, Sox2, Klf4 or c-Myc in 18 out of the 40 cancer types investigated. Furthermore, within a given tumor category these genes are associated with tumor progression or bad prognosis. A key goal in cancer research is to identify the mechanism by which cancer stem cells arise and self-renew. The overexpression of Oct3/4, Sox2, Klf4 and/or c-Myc could contribute to the pathologic self-renewal characteristics of cancer stem cells.

show abstract

“…The latter study highlights the transcription factor, OCT4, as having a pivotal role in maintaining the chemoradioresistant properties of lung cancer CD133 + cells. Embryonic stem cell marker, OCT4 (having the isoforms A and B), has been a focus in cancer stem cell research due to its recent prevalence in malignant settings (9,21,22).…”

Section: Introductionmentioning

confidence: 99%

Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed

Schmid¹

2010

Int J Oncol

View full text Add to dashboard Cite

Abstract. Malignant pleural mesothelioma (MPM) is a lethal cancer of the mesothelium with high chemotherapeutic resistance via unknown mechanisms. A prevailing hypothesis states that cancer stem cells (CSCs) persist in tumors causing relapse after chemotherapy, thus, rendering these cells as critical targets responsible for tumor resistance and recurrence. We selected candidate CSC markers based on expansion under hypoxic conditions, a hallmark for the selection of chemoresistant cells; and investigated the expression of CSC markers: CD133, Bmi-1, uPAR and ABCG2 in three MPM cell lines and normal mesothelial cells by quantitative RT-PCR. Furthermore, we evaluated the chemotherapeutic resistance associated with each CSC marker by determining the change in CSC marker-mRNA levels as an index of drugresistance following treatment with either cisplatin or pemetrexed. We demonstrate the expression of CSC markers: CD133, Bmi-1, uPAR and ABCG2 in both normal and MPM cell lines. Bmi-1 + , uPAR + and ABCG2 + cells show a distinct role in conferring chemoresistance to cisplatin and pemetrexed in the malignant setting. By contrast, these markers have no apparent participation in chemoresistance to drug treatments in normal mesothelial cells. Intriguingly, CD133 revealed chemoresistant properties in both normal mesothelial and malignant pleural mesothelioma cells. This study provides evidence of putative CSCs conferring drug-resistance to cisplatin and pemetrexed in MPM cell lines. Specific targeting of these drug-resistant cells, while considering the functional heterogeneity of the MPM subtypes, may contribute to more focused and effective chemotherapeutic regimens for malignant pleural mesothelioma.

show abstract

Oct4A is expressed by a subpopulation of prostate neuroendocrine cells

Cited by 81 publications

References 54 publications

Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells

Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells

Embryonic stem cell markers expression in cancers

Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed

Contact Info

Product

Resources

About